Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.

Content Provider	Semantic Scholar
Author	Pourgholami, Mohammad Hossein Cai, Zhao Yan Lu, Ying Wang, Lisa Morris, David L.
Copyright Year	2006
Abstract	PURPOSE Angiogenesis and vessel hyperpermeability are the two factors leading to the formation of ascites. Vascular endothelial growth factor (VEGF) plays a pivotal role in malignant ascites formation. We have recently shown that albendazole inhibits peritoneal growth of human colorectal cancer cells (HT-29). The present study was designed to find out if albendazole can suppress ascites formation in ascites-producing peritoneal carcinomatosis. EXPERIMENTAL DESIGN Female nude mice bearing peritoneal tumors of human ovarian cancer cells (OVCAR-3) were treated with albendazole. Following i.p. inoculation and ascites development, mice were given i.p. albendazole (150 mg/kg) or the vehicle x 3 weekly for 4 weeks. RESULTS Whereas vehicle-treated mice developed overt ascites requiring repeated aspiration, ascites formation in the albendazole-treated mice was markedly suppressed. As a result of this, 7 of 10 mice from the control group had to be euthanized before the course of treatment was over. Suppressed ascites production and reduced tumor vascularity observed was a result of dramatic reduction in tumor VEGF production as revealed by profoundly lower VEGF ascites fluid and plasma levels. In vitro, incubation of SKOV-3 cells with various concentrations of albendazole led to significant dose-dependent inhibition of VEGF secretion. Examination of floating tumor cells collected from the peritoneal wash revealed profound down-regulation of VEGF mRNA in albendazole-treated mice. CONCLUSIONS These findings suggest for the first time that in nude mice bearing OVCAR-3 peritoneal tumors, by inhibiting VEGF production, albendazole abolishes tumor angiogenesis and ascites formation.
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://clincancerres.aacrjournals.org/content/clincanres/12/6/1928.full.pdf
PubMed reference number	16551879v1
Volume Number	12
Issue Number	6
Journal	Clinical cancer research : an official journal of the American Association for Cancer Research
Language	English
Access Restriction	Open
Subject Keyword	Albendazole Blood Vessel Tissue Colorectal Carcinoma Down-Regulation Endothelial Growth Factors Growth Factor HT29 Cells Inhibition Malignant neoplasm of ovary OVCAR-3 Peritoneal Carcinomatosis Peritoneal Neoplasms Tumor Angiogenesis cancer cell malignant ascites mg/kg ovarian neoplasm
Content Type	Text
Resource Type	Article